To further explore the mechanisms involved in the differences in drug responses, RNA-seq analysis was carried out on a selection of TP53WT primary CLL samples either resistant or sensitive to the MDM2 inhibitor RG7388, to define differentially expressed genes and pathways activated by RG7388 compared to untreated controls. This evidence concerns the gene MDM2 and B-cell chronic lymphocytic leukemia.